Definitive Contract HHSN272201600038C

This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Profectus Biosciences, Inc., a small business concern, for the development of novel vaccine technologies and strategies. The contract has a total potential value of $322,336.00 and was awarded under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed...

This is a Cost Plus Fixed Fee contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Profectus Biosciences, Inc., a small business. The contract, with a potential value of $3,383,522.51, is for research and development in the biomedical field, specifically focused on applied research and exploratory development of vaccine technologies. The contract does not have a set-aside designation....

This federal contract award, identified as HHSN272201501390P, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services. The $6,130.60 firm-fixed-price purchase order was awarded to Invivogen, a for-profit organization, on September 23, 2015 for the product "AMBIS 1755049 ODN1826, 5MG; PRODUCT ID TLRL-1826-5." The contract did not have a set-aside designation and is scheduled for completion on...

This federal contract award, valued at $16,731,358.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute. The contract is for the continued development of vaccine candidates for biodefense, antimicrobial resistance, emerging infectious diseases, and respiratory pathogens. No set-aside designation was used. AAHI has subcontracted with several institutions, including Emory...

This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services. The contract was awarded to Promega Corporation, a global life sciences company, for an "ASSAY SYSTEM" with a total ceiling value of $37,494.60. The contract was a firm fixed-price purchase order with an ultimate completion date of August 24, 2016. Promega, which does business as Promega Corp, is a...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $449,984 firm fixed-price contract to Applied Biotechnology Institute Inc., a veteran-owned small business, to develop a mucosal prophylactic vaccine against coccidioidomycosis. The contract, with a completion date of August 30, 2018, is a direct result of NIAID's research efforts in the area of allergy and infectious diseases. Applied Biotechnology Institute Inc. has previously received federal grants from NIAID and the...

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...

This is a $224,981.00 firm-fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to Epitogenesis Inc., a minority-owned, economically disadvantaged women-owned small business. The contract is for the development of "A NUTRITIVE VACCINE ADJUVANT AGAINST INFLUENZA" and has a period of performance ending on September 14, 2015. The contract was set aside for small businesses.

<p>This federal contract award with ID HHSN272201200386P was made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to the small business contractor IG Assets Inc. The $99,750.00 firm fixed-price purchase order contract was awarded on April 10, 2012 with a completion date of April 28, 2013. The contract is designated as a total small business set-aside.</p>

This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Sanofi Pasteur Biologics, LLC, a foreign-owned for-profit organization. The contract is for the development and testing of a modified vaccinia Ankara (MVA) vaccine, with a ceiling value of $12,667,339.96. The contract is a definitive, cost-plus-fixed-fee contract type, with a final completion date of January 8, 2007. The...